HHS is proposing temporary enforcement priorities and side effect reporting for compounded peptides, with more specifics in Becker's rundown.
Recap by typeshit. Full story at Becker's Hospital Review.
Bloomberg reports the Kennedy plan to widen peptide access comes with a side effect reporting rule for compounding pharmacies.
A Facebook user explains that compounded GLP-1 versions were allowed during the branded drug shortage and flags what that means for people still using them.
Sahpra reports about 600 fake medicine complaints this year, and new compounding rules aren't due until early next year, which industry head Stavros Nicolaou calls too late.
The Warrington Guardian reports charges against staff over the theft of weight-loss injections valued at around £20,000.
A link post sharing @DigitalMehmet's take on tirzepatide and semaglutide beyond diabetes, with hopes for joint and brain conditions. Light on detail.
He describes tirzepatide acting on appetite hormones and cites a 72-week trial where adults without diabetes lost an average 15% to 21% of weight, depending on dose.
Loading…